This study examined how N6-methyladenosine (m6A) mRNA methylation regulates pancreatic α-cell identity, function, and plasticity — including amino acid-stimulated glucagon secretion and α-to-β-cell conversion — using α-cell-specific Mettl14 knockout mice and m6A-eCLIP to identify direct targets.
Loss of m6A (via α-cell-specific Mettl14 deletion) impaired amino acid-stimulated glucagon secretion, reduced α-cell mass, increased β-cell mass, and promoted α-to-β-cell conversion; mechanistically, YY1 was identified as a direct m6A-sensitive target whose elevation drives signaling rewiring and erosion of α-cell identity.
Findings are based on a mouse knockout model, so direct translation to human α-cell biology requires further validation; the newly formed β-like cells showed features of incomplete maturation, raising questions about their functional adequacy; the study does not establish whether m6A manipulation could be therapeutically targeted in vivo without off-target endocrine effects.
While not yet clinically actionable, these findings reveal that epitranscriptomic m6A modification is a key regulator of α-cell state and endocrine plasticity, pointing to a potential future strategy for driving α-to-β-cell conversion in diabetes.